SCHEMBL526906

SCHEMBL526906

CNS(=O)(=O)c1ccc([N+](=O)[O-])cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 7/20 1.00
CA1 P00915 5/20 1.00
CA12 O43570 5/20 1.00
CA9 Q16790 5/20 1.00
CA14 Q9ULX7 4/20 1.00
CA3 P07451 3/20 1.00
CA4 P22748 3/20 1.00
CA6 P23280 3/20 1.00
CA5A P35218 3/20 1.00
CA7 P43166 3/20 1.00
CA13 Q8N1Q1 3/20 1.00
CA5B Q9Y2D0 3/20 1.00
MMP2 P08253 2/20 0.66
MMP1 P03956 1/20 0.66
MMP9 P14780 1/20 0.66
MMP8 P22894 1/20 0.66
MMP13 P45452 1/20 0.66
SMN1; SMN2 Q16637 2/20 0.57
GAA P10253 1/20 0.57
ALDH1A1 P00352 3/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL620004 0.89 CA2 (0.80) CA2CA1CA12CA9CA14
SCHEMBL29631718 0.86 CA2 (0.76) CA2CA1CA12CA9CA14
SCHEMBL10494215 0.83 CA2 (0.70) CA2CA1CA12CA9CA14
SCHEMBL7629070 0.82 SMN1; SMN2 (0.80) CA2CA1CA12CA9CA14
SCHEMBL12517868 0.82 CA2 (0.69) CA2CA1CA12CA9CA14
SCHEMBL23703081 0.80 CA2 (0.67) CA2CA1CA12CA9CA14
SCHEMBL922350 0.80 CA2 (0.71) CA2CA1CA12CA9CA14
SCHEMBL6308870 0.79 CA2 (0.66) CA2CA1CA12CA9CA14
SCHEMBL10531768 0.79 CA2 (0.66) CA2CA1CA12CA9CA14
SCHEMBL12353364 0.79 CA2 (0.66) CA2CA1CA12CA9CA14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 128 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117800852-A Synthetic method of natural product salt spike grass alkali 江西师范大学 2024-04-02 CN claimed
CN-115012007-A Copper-graphene electroplating solution, copper-graphene composite foil and preparation method thereof 江西理工大学 2022-09-06 CN claimed
CN-108117499-B Preparation method of alpha aryl amidine imine derivative 上海应用技术大学 2020-10-09 CN claimed
CN-108117499-A A kind of preparation method of α aryl amidine imine derivative 上海应用技术大学 2018-06-05 CN claimed
WO-2026106912-A1 RAS INHIBITORS Revolution Medicines, Inc. (US) 2026-05-21 WO disclosed
EP-4719413-A1 INHIBITORS OF CANINE JANUS KINASE AND USES THEREOF Animol Discovery, Inc. (US) 2026-04-08 EP disclosed
US-20260092070-A1 INHIBITORS OF CANINE JANUS KINASE AND USES THEREOF ANIMOL DISCOVERY INC (US) 2026-04-02 US disclosed
EP-4563571-A1 PRMT5 INHIBITORS Beijing Earthwise Technology Co., Ltd. (CN) 2025-06-04 EP disclosed
US-12275720-B2 Small molecule inhibitors of galectin-3 BRISTOL-MYERS SQUIBB COMPANY (US) 2025-04-15 US disclosed
CN-119731154-A PRMT5 inhibitors 北京望实智慧科技有限公司 2025-03-28 CN disclosed
WO-2024246837-A1 INHIBITORS OF CANINE JANUS KINASE AND USES THEREOF ANIMOL DISCOVERY, INC. (US) 2024-12-05 WO disclosed
US-20240366518-A1 COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF LIFE EDIT THERAPEUTICS, INC. 2024-11-07 US disclosed
CN-1276789-A 4-aminothiazole derivatives, their preparation and their use as inhibitors of cyclin dependent kinases AGOURON PHARMA (US) 2000-12-13 CN disclosed
EP-1056732-A2 4-AMINOTHIAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF CYCLIN-DEPENDENT KINASES AGOURON PHARMACEUTICALS, INC. (US) 2000-12-06 EP disclosed
US-5932598-A NOVEL SUBSTITUTED SULFONAMIDE COMPOUNDS USEFUL AS PRODRUGS; ADMINISTERING TO TREAT INFLAMMATION-ASSOCIATED PAIN DUE TO CANCER, DENTAL PAIN; CYCLOOXYGENASE-2 INHIBITORS G. D. SEARLE & CO. (US) 1999-08-03 US disclosed
WO-1999032466-A1 SUBSTITUTED BENZENESULFONAMIDE DERIVATIVES AND THEIR PHARMACEUTICAL USE NOVARTIS AG (CH) 1999-07-01 WO disclosed
WO-1999021845-A2 4-AMINOTHIAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF CYCLIN-DEPENDENT KINASES AGOURON PHARMACEUTICALS, INC. (US) 1999-05-06 WO disclosed
EP-0892791-A1 SUBSTITUTED BENZENESULFONAMIDE DERIVATIVES AS PRODRUGS OF COX-2 INHIBITORS G.D. SEARLE & CO. (US) 1999-01-27 EP disclosed
WO-1997038986-A1 SUBSTITUTED BENZENESULFONAMIDE DERIVATIVES AS PRODRUGS OF COX-2 INHIBITORS G.D. SEARLE & CO. (US) 1997-10-23 WO disclosed
CN-1160400-A Pyrrolyl tetrahydrobenzoquinoxalinediones, their preparation and their use as glutamate receptor antagonists BASF AG (DE) 1997-09-24 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12275720-B2 Small molecule inhibitors of galectin-3 LGALS3, LGALS3BP, LGALS1 CA2 656/4885CA1 795/4885CA12 170/4885
US-20240366518-A1 COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF POLRMT, POLN, NSUN2 CA2 4801/4885CA1 4733/4885CA12 3873/4885
US-20260092070-A1 INHIBITORS OF CANINE JANUS KINASE AND USES THEREOF JAK1, JAK3, JAK2 CA2 1072/4885CA1 2926/4885CA12 4095/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.